Company BioNexus Gene Lab Corporation Other OTC
Equities
BGLC
US0906281086
Biotechnology & Medical Research
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Chemrex
99.8
%
| 11 | 99.1 % | 10 | 99.8 % | -10.03% |
MRNA Scientific Malaysia
0.2
%
| 0 | 0.9 % | 0 | 0.2 % | -74.72% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Malaysia
100.0
%
| 11 | 100.0 % | 10 | 100.0 % | -10.60% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Lee Su-Leng Tan
CEO | Chief Executive Officer | 40 | 23-07-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Chee Keong Yap
BRD | Director/Board Member | 68 | 22-03-06 |
Wei Foong Lim
BRD | Director/Board Member | 48 | 12-10 |
Lee Su-Leng Tan
CEO | Chief Executive Officer | 40 | 23-07-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 17,667,663 | 6,294,165 ( 35.63 %) | 0 | 35.63 % |
Company contact information
BioNexus Gene Lab Corp.
Tower B, Vertical Business Suite Bangsar South, 8 Jalan Kerinchi
59200, Kuala Lumpur
+60 1 307 241 6898
http://www.bionexusgenelab.com![address BioNexus Gene Lab Corporation(BGLC)](https://cdn.zonebourse.com/static/address/112544271.png)
Sector
Sales per Business
1st Jan change | Capi. | |
---|---|---|
+16.59% | 44.87B | |
-10.62% | 37.8B | |
+40.49% | 37.61B | |
+29.92% | 31.32B | |
-9.78% | 27.4B | |
+12.34% | 26.32B | |
+41.53% | 14.07B | |
+31.49% | 12.5B | |
-7.40% | 11.23B |